| Autor: |
Schwarz, Esther I., Martinez-Lozano Sinues, Pablo, Bregy, Lukas, Gaisl, Thomas, Garcia Gomez, Diego, Gaugg, Martin T., Suter, Yannick, Stebler, Nina, Nussbaumer-Ochsner, Yvonne, Bloch, Konrad E., Stradling, John R., Zenobi, Renato, Kohler, Malcolm |
| Předmět: |
|
| Zdroj: |
Thorax; Feb2016, Vol. 71 Issue 2, p110-117, 8p, 1 Color Photograph, 1 Diagram, 4 Charts, 1 Graph |
| Abstrakt: |
Background: Obstructive sleep apnoea (OSA) is highly prevalent and associated with cardiovascular and metabolic changes. OSA is usually diagnosed by polysomnography which is time-consuming and provides little information on the patient's phenotype thus limiting a personalised treatment approach. Exhaled breath contains information on metabolism which can be analysed by mass spectrometry within minutes. The objective of this study was to identify a breath profile in OSA recurrence by use of secondary-electrospray-ionization-mass spectrometry (SESI-MS).Methods: Patients with OSA effectively treated with CPAP were randomised to either withdraw treatment (subtherapeutic CPAP) or continue therapeutic CPAP for 2 weeks. Exhaled breath analysis by untargeted SESI-MS was performed at baseline and 2 weeks after randomisation. The primary outcome was the change in exhaled molecular breath pattern.Results: 30 patients with OSA were randomised and 26 completed the trial according to the protocol. CPAP withdrawal led to a recurrence of OSA (mean difference in change of oxygen desaturation index between groups +30.3/h; 95% CI 19.8/h,40.7/h, p<0.001) which was accompanied by a significant change in 62 exhaled features (16 metabolites identified). The panel of discriminating mass-spectral features allowed differentiation between treated and untreated OSA with a sensitivity of 92.9% and a specificity of 84.6%.Conclusion: Exhaled breath analysis by SESI-MS allows rapid and accurate detection of OSA recurrence. The technique has the potential to characterise an individual's metabolic response to OSA and thus makes a comprehensible phenotyping of OSA possible.Trial Registration Number: NCT02050425 (registered at ClinicalTrials.gov). [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
